Together, these data show that SpiD3 treatment enhanced ecto-CALR expression in both HG-3 and OSU-CLL cell lines and primary CLL cells comparable to the known CALR-translocating and ICD-inducing agent etoposide (Figure 1). Here, CALR is linked to B-cell chronic lymphocytic leukemia.